Reuters logo
3 months ago
BRIEF-Roche announces FDA approval of companion diagnostic to identify ALK-positive non-small cell lung cancer patients
June 1, 2017 / 3:29 PM / 3 months ago

BRIEF-Roche announces FDA approval of companion diagnostic to identify ALK-positive non-small cell lung cancer patients

June 1 (Reuters) - Roche Holding AG

* Roche announces FDA approval of companion diagnostic to identify ALK-positive non-small cell lung cancer patients

* ‍Ventana ALK CDX assay identifies ALK-positive NSCLC patients eligible for treatment with novartis drug zykadia, expanding current treatment options​

* ‍Ventana ALK (D5F3) CDX assay is available for use on benchmark IHC/ISH instruments​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below